{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-116086","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.549266+00:00","generated_at":"2026-05-30T01:45:35.534701+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Annovis Bio Q3 net loss $0.97/share; FDA clears Phase 3 studies for buntanetap in early AD","bullets":["FDA granted clearance for pivotal Phase 3 studies: a 6-month symptomatic and an 18-month disease-modifying trial in early Alzheimer's disease.","Cash and cash equivalents of $13.6M as of Nov 8, 2024; management says runway extends into Q1 2025 Phase 3 start.","Q3 total operating expenses were $4.4M, down sharply from $14.9M a year ago; R&D was $2.7M vs $13.9M.","Net loss per share (basic/diluted) was $0.97, compared to $1.63 in Q3 2023.","Filed three new combination-therapy patents for buntanetap with dulaglutide, sildenafil, or both."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-116086","json":"https://secwatch.observer/filing/0001104659-24-116086.json","markdown":"https://secwatch.observer/filing/0001104659-24-116086.md","text":"https://secwatch.observer/filing/0001104659-24-116086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924116086/0001104659-24-116086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924116086/tm2427939d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:45:35.534701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}